Ovid Therapeutics Showcases Neurotherapeutics Pipeline Targeting Neural Hyperexcitability
I'm PortAI, I can summarize articles.
Ovid Therapeutics Inc. has updated its neurotherapeutics pipeline, focusing on conditions driven by neural hyperexcitability. Key developments include advancing OV329 for drug-resistant seizures, with Phase 2a results expected in mid-2027, and developing OV4071 for psychosis and schizophrenia. OV4041 targets anxiety and Rett syndrome. The company has a cash runway to fund operations into the second half of 2028. This update was published by Ovid Therapeutics on December 18, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments